Connect your AI

Ultragenyx Pharmaceutical RARE Price / book

Price / book at other companies

Eli LillyLLY

26.3×-20.7×

AmgenAMGN

20.6×-6.3×

Ionis PharmaceuticalsIONS

25.2×+15.2×

Arrowhead ResearchARWR

14.3×+11.7×

CRISPR TherapeuticsCRSP

2.5×+0.9×

ModernaMRNA

2.7×+1.6×

Other financials

Income statement

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Calculated from Ultragenyx Pharmaceutical’s reported figures.

market cap/total stockholders equity=316.5×

Based on the most recent quarter.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ultragenyx Pharmaceutical's price / book?: Ultragenyx Pharmaceutical (RARE) reported price / book of 316.5× in Q3 2025.
How has Ultragenyx Pharmaceutical's price / book changed year-over-year?: Ultragenyx Pharmaceutical's price / book increased by 2182.4% year-over-year, from 13.9× to 316.5×.
What is the long-term trend for Ultragenyx Pharmaceutical's price / book?: Over 4 years (2020 to 2024), Ultragenyx Pharmaceutical's price / book has grown at a 16.8% compound annual growth rate (CAGR), from 8.2× to 15.2×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.